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Background.TheexpressionofCD24hasbeendetectedinawidevarietyofhumanmalignancies.DownregulationofCD24inhibits
proliferation and induces apoptosis in tumor cells, whereas its upregulation increases tumor growth and metastasis. However,
no data on CD24 protein levels in retinoblastoma are available, and the mechanism of CD24 involvement in retinoblastoma
progress has not been elucidated. The aim of this study was to explore the expression proﬁle of CD24 in the retinoblastoma tumor
samples and to correlate with clinicopathological parameters. Methods. Immunohistochemistry was performed for CD24 on the
archival paraﬃn sections of retinoblastoma and correlated with clinicopathological features. Western blotting was performed
to conﬁrm immunoreactivity results. Results. CD24 immunoreactivity was observed in 72.0% (36/50) of the retinoblastoma
specimens. Among the 35 low-risk tumors, CD24 was expressed in 62.9% (22/35) tumors and among the 15 high-risk tumors,
CD24 was expressed in 93.3% (14/15) tumors. High-risk tumors showed signiﬁcantly increased expression of CD24 compared
to tumors with low-risk (P<0.05). Conclusions. This is the ﬁrst correlation between CD24 expression and histopathology in
humanretinoblastoma.OurstudyshowedincreasedexpressionofCD24inhighrisktumorscomparedtolowrisktumors.Further
functional studies are required to explore the role of CD24 in retinoblastoma.
1.Introduction
Retinoblastoma is the most common primary intraocular
malignancy in children [1]. It is more frequent in some
developing areas, such as Latin America, Africa, China, and
India [2]. Factors that play a role in tumor invasion and
metastasisincludeearlygeneticeventssuchasincreasedcopy
number of chromosome 6p and 1q, and late events such
as high levels of telomerase activity, loss of chromosome
1p, and p53 inactivation [3]. Retinoblastoma is diagnosed
late, usually when extraocular dissemination has occurred
and the prognosis is poor. Primary chemoreduction is used
forintraocularretinoblastomaandsystemicchemotherapyis
used following enucleation in patients with optic nerve and
deep choroidal invasion, orbital extension, and metastatic
disease. New treatment modalities, such as subconjunctival
injection, selective ophthalmic artery injection, and vitreous
injection, are being investigated and have achieved favorable
results [4]. Although many modalities are used, almost half
of eyes with retinoblastoma have to be enucleated. Thus,
there is an urgent need to further study the biology and
molecular mechanisms of retinoblastoma and identify the
speciﬁc proteins that cause tumor progression and predict
prognosis in order to improve the therapeutic outcome of
patients with retinoblastoma.
CD24 is a small, heavily glycosylated, phosphatidyli-
nositol-anchored ucin-like cell surface protein [5]. Several
studies have identiﬁed CD24 as an alternative ligand for
P-selectin, an adhesion molecule which is expressed by
activated endothelial cells and platelets [6]. Functionally,
it is considered to play a critical role in the metastasis of
tumor cells through P-selectin. Many tumor cell lines can
bind to platelets via P-selectin, and CD24 expression might
enhance the metastatic potential of tumor cells [7]. Recently,
several studies have investigated CD24 overexpression in a
wide variety of human malignancies lung cancer, chorio-
carcinoma, cholangiocarcinoma, glioma, pancreatic cancer,
prostatic cancers, renal cell carcinoma, and ovarian and2 Journal of Biomedicine and Biotechnology
breast cancers [8–15]. This increased expression is usually
tied with a more aggressive course of the disease. CD24
positivity was signiﬁcantly related to younger patient age,
higher pT stages, and higher PSA relapse rate in prostatic
adenocarcinomas [10]. Wei et al. have shown that CD24 is
overexpressed in pancreatic cancer cell lines in comparison
to nine normal pancreatic cell lines [11]. In hepatocellular
carcinomas,CD24expressionwasalsocorrelatedwithserum
levels of HBs-Ag, elevated serum AFP levels, and p53
mutations[12].Leeetal.notedstrongCD24staininginrenal
cell carcinoma irrespective of the histological tumor type
[13] .Ar e c e n ts t u d yb yS m i t he ta l .r e p o r t e dC D 2 4o v e r e x -
pression in bladder cancer compared to normal urothelium;
however, no correlation with tumor stage and grade was
noted. Additionally, bladder cancer patients with strong
CD24 immunoreactivity tended to have a shorter disease-
free survival [14]. Moreover, it has been demonstrated that
the down-regulation of CD24 inhibits proliferation and
induces apoptosis in tumor cells, whereas its up-regulation
increases tumor growth and metastasis. Although there have
been substantial advances in the understanding of the basic
biology and pathogenesis of retinoblastoma, there is no
data on CD24 protein levels in retinoblastoma, and the
mechanismofCD24involvementinretinoblastomaprogress
has not been elucidated. The purpose of this study was
to investigate if CD24 is present in retinoblastoma and to
evaluate the correlation between CD24 expression and the
severity of the malignancy of this tumor.
2.MaterialsandMethods
2.1. Patients and Tissue Samples. This study was approved by
theResearchEthicsCommitteeofDaPingHospital,Research
Institute of Surgery Third Military Medical University,
Chongqing, China. Written informed consent was obtained
from all of the patients. All specimens were handled and
made anonymous according to the ethical and legal stan-
dards.
Fifty tumors were available from 50 eyes for the present
study.Amongthem,thereweretumorsfrom35malesand15
females. The age ranged from 1 month to 8 years. (median =
22 months). There were 38 unilateral retinoblastomas and
12 bilateral retinoblastomas. Ten fresh tumors were used for
studying the expression of CD24.
2.2. Histopathological Information. There were 35 tumors
with no massive invasion of choroid or optic nerve (lower
risk to extraocular relapse) and 15 tumors with invasion
of choroid/optic nerve/orbit (higher risk to extraocular
relapse). Among the 15 high-risk tumors, 2 tumors had
diﬀuse choroidal invasion, 2 tumors with postlaminar optic
nerve invasion. There are 5 tumors with both diﬀuse
choroidalandpost-laminarONinvasion,2tumorswithboth
diﬀusechoroidalandprelaminarONinvasion,2tumorswith
focal choroidal and post-laminar ON invasion, and 1 tumor
with post-laminar optic nerve invasion with surgical end
involved. There was 1 tumor with orbital invasion. There
were 31 tumors with poorly diﬀerentiated cells, 12 tumors
with well-diﬀerentiated and 7 tumors with moderately
diﬀerentiated cells.
2.3. Immunohistochemistry Assay. Formalin-ﬁxed, paraﬃn-
embedded, sectioned tissues (5μm thick) were immunos-
tained using the Labelled Streptavidin Biotin 2 System
(BioGenex; San Ramon, CA, USA). Following peroxidase
blocking with 0.3% H2O2/methanol for 30min, speci-
mens were blocked with phosphate-buﬀered saline (PBS)
containing 5% normal horse serum (Vector Laboratories
Inc., Burlingame, CA, USA). All incubations with mouse
monoclonal antibody CD24 (Neomarkers, Clone 24C02,
Fremont, CA, USA) at 1:100 dilution were carried out
overnight at 4◦C. Then the specimens were brieﬂy washed in
PBSandincubatedatroomtemperaturewiththeanti-mouse
antibody and avidin-biotin peroxidase (Vector Laboratories
Inc., Burlingame, CA, USA). The specimens were then
washed in PBS and color-developed by diaminobenzidine
solution (Dako Corporation, Carpinteria, CA, USA). After
washing with water, specimens were counterstained with
Meyer’s hematoxylin (Sigma Chemical Co., St Louis, MO,
USA). For CD24-negative controls, immunohistochemistry
was performed using normal mouse immunoglobin with a
dilution of 1:100 (0.4μg) and normal goat immunoglobin
with a dilution of 1:100 (8μg/mL).
Assessment of immunohistochemical staining was eval-
uated by two independent pathologists. The CD24-positive
cells showed immunoreactivity in the cytoplasm of tumor
cells. Randomly 10 vital tumor ﬁelds were scanned for
protein expression and percentage of positive tumor cells
was noted for each ﬁeld. Then ﬁnally the average expression
was calculated from the 10 values for the entire slide.
Depending on the percentage of positive cells, 4 categories
were established: 0, no positive cells; 1+, positive cells in
less than one-third (faint); 2+, positive cells in 33∼67%
(heterogeneous); 3+, positive cells in more than two-thirds
(positive) of total tumor cell population.
2.4. Western Blot Analysis. Retinoblastoma tissues were
homogenized in lysis buﬀer (PBS, 1% nonidet P-40 (NP-
40), 0.5% sodium deoxycholate, 0.1% sodium dodecyl sul-
fate (SDS), 100μg/mL aprotinin, 100μg/mL phenylmethyl-
sulfonyl ﬂuoride (PMSF), sodium orthovanadate) at 4◦C
throughout all procedures, and sonicated for 70s, then
added to 300μg PMSF per gram of tissue and incubated
on ice for 30min, followed by centrifugation at 15,000rpm
for 20min at 4◦C. The protein content was determined
according to Bradford’s method (Bradford, 1976), with
bovine serum albumin used as a standard. Equal amounts
of protein were separated electrophoretically on 7.5% SDS-
polyacrylamide gels and transferred onto polyvinylidene
diﬂuoride membranes (Roche; Basel, Switzerland). The
membranes were probed with monoclonal mouse anti-
human CD24 (SC-7034, 1:500, Santa Cruz Biotechnol-
ogy). The expression level of CD24 was determined by
incubating the membranes with horseradish peroxidase-
conjugated anti-mouse immunoglobulin G (1:3000 dilu-
tion) and enhanced chemiluminescence reagent (Pierce;
Minneapolis, MN, USA), according to the manufacturers’Journal of Biomedicine and Biotechnology 3
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Figure 1: Immunohistochemical staining for CD24 in human retinoblastoma tissues (original magniﬁcation ×200). (a) CD24 staining is
negative in non-neoplastic retina; (b) CD24-positive expression was found in the cytoplasm of retinoblastoma tissues.
suggested protocols. Detection of positivity was by using
ECL system (Amersham Pharmacia) or the Supersignal West
Femto Maximum Sensitivity Substrate (Pierce).
2.5. Statistical Analysis. All computations were carried out
using the software of SPSS version13.0 for Windows (SPSS
Inc, IL, USA). Data were expressed as means ± standard
deviation(SD).Mann-WhitneyU testwasusedtodetermine
association of immunoreactivity of CD24 with tumor inva-
sion and diﬀerentiation. For statistical purposes, moderately
diﬀerentiated and well-diﬀerentiated tumors were grouped
together and were compared with poorly diﬀerentiated
tumors. Diﬀerences were considered statistically signiﬁcant
when P was less than 0.05.
3. Results
3.1. Immunohistochemical Staining of CD24 Protein in Hu-
man Retinoblastoma Tissues. Immunohistochemistry anal-
ysis showed no positive CD24 protein expression in the
nonneoplastic retina (Figure 1(a)). CD24 immunoreactivity
was observed in the cytoplasm of retinoblastoma specimens
with varying levels of percentage tumor staining and intensi-
ties (Figure 1(b)). CD24 immunoreactivity was observed in
72.0% (36/50) of the retinoblastoma specimens.
We observed that tumors with invasion showed sig-
niﬁcantly higher expression of CD24 compared to tumors
without invasion (P<0.05). The immunoreactivity of CD24
in high-risk and low-risk tumors is shown in Table 1.T h e
raw data of the individual immunoscores for CD24 in the
high-risk and low-risk tumors are available in Tables 2 and
3, respectively. Among the 35 low-risk tumors, CD24 was
expressed in 62.9% (22/35) tumors and among the 15 high-
risk tumors, CD24 was expressed in 93.3% (14/15) tumors.
High-risk tumors showed signiﬁcantly increased expression
of CD24 compared to tumors with low risk (P<0.05).
Lane 0123456789 1 0
CD24
(35 ∼ 45 kDa)
Figure 2: Western blot analysis for CD24 protein expression in
retinoblastoma tissues, with non-neoplastic retina as control. The
pictureshowsthatCD24wasnegativeinnon-neoplasticretina(lane
0), strongly expressed in 5 (83.3%, lanes 1∼5) and faintly expressed
in 1 (16.7%, lanes 6) high-risk tumors, whereas it was strongly
expressedin2(50.0%,lanes7∼8)andfaintlyexpressedin2(50.0%,
lanes 9∼10) low-risk tumors.
3.2. Western Blot Analysis on Expression Levels of CD24
Protein in Human Retinoblastoma Tissues. Consistent with
the results of immunohistochemical staining, western blot
analysis also showed no CD24 protein in the non-neoplastic
retina (lane 0), but positive expression in the retinoblastoma
tissues which showed a single band of approximately 35∼
45kDa for CD24 protein in all the tumors (Figure 2). Of
the 10 tumors studied, 6 tumors were of high-risk and 4
tumors were of low-risk. CD24 was strongly expressed in 5
(83.3%, lanes 1∼5) and faintly expressed in 1 (16.7%, lanes
6) high-risk tumors, whereas it was strongly expressed in 2
(50.0%, lanes 7∼8) and faintly expressed in 2 (50.0%, lanes
9∼10) low-risk tumors, also suggesting high-risk tumors
showedsigniﬁcantlyincreasedexpressionofCD24compared
to tumors with low-risk (P<0.05).
4. Discussion
Tothebestofourknowledge,thisistheﬁrststudytodemon-
strate the correlation between CD24 and retinoblastoma.
There are three main ﬁndings in the present study. At ﬁrst,
there was no CD24 expression in non-neoplastic retina;
secondly, positive CD24 protein expression was observed
in more than half of the retinoblastoma tissues by both4 Journal of Biomedicine and Biotechnology
Table 1: The expression of CD24 protein in high-risk and low-risk retinoblastoma.
Group No. of cases
CD24 immunohistochemical staining
Positive Heterogeneous Faint Negative
Overall cohort 50 19 11 6 14
High-risk tumors 15 9 4 1 1
Low-risk tumors 35 10 7 5 13
P value <0.05
Table 2: The expression of CD24 protein and clinicopathological features of retinoblastoma tissues with high risk of extraocular relapse.
Case no. Age/sex Clinicopathological features CD24 positivity (%)
1 3mon/M OS: PD, Post Lam ON Inv 30
2 5/M OD: PD, rectus orbital invasion 80
3 3/M OS: PD, Diﬀ Ch Inv 40
4 7/M OS: PD, Post Lam ON Inv 70
5 2/M OS: PD, Diﬀ Ch, Post Lam ON Inv 10
6 20mon/F OS: PD, Diﬀ Ch, Post Lam ON Inv 30
7 5/M OS: PD, Diﬀ Ch, Pre Lam ON inv 60
8 3/M OS: PD, Diﬀ Ch, Post Lam ON Inv 0
9 1/F OD: PD, Post Lam ON Inv with SE involved 70
10 2/F OS: PD, Diﬀ Ch, Pre Lam ON Inv 50
11 1/F OD: PD, Diﬀ Ch Inv 60
12 4/M OS: PD, Diﬀ Ch Inv 80
13 3/M OD: PD, Focal Ch, Post Lam ON Inv 90
14 2/F OS: PD, Diﬀ Ch, Post Lam ON Inv 50
15 2/M OD: PD, Focal Ch, Post Lam ON Inv 70
N o t e :m o n :m o n t h s ;M :m a l e ;F :f e m a l e ;O D :r i g h te y e ;O S :l e f te y e ;P D :p o o r l yd i ﬀerentiated; MD: moderately diﬀerentiated; WD: well diﬀerentiated; UL:
unilateral disease; BL: bilateral disease; Diﬀ Ch Inv: diﬀused choroidal invasion of tumor; Focal Ch Inv: focal invasion of tumor cells into choroids; Pre Lam
ON Inv: pre-laminar invasion of optic nerve; Post Lam ON Inv: post-laminar invasion of the optic nerve.
immunohistochemistry and western blot analysis; and
thirdly the level of CD24 was signiﬁcantly higher in the
retinoblastoma tissues with high risk of extraocular relapse
than those with low risk of extraocular relapse. These
results suggest that CD24 protein may be involved in the
pathogenesis of retinoblastoma, and the level of CD24
protein expression may be associated with the severity of
retinoblastoma.
CD24 was identiﬁed 30 years ago [16]. Since then, it
has been extensively used as a marker for the diﬀerentiation
of hematopoietic and neuronal cells, in addition to tissue
and tumor stem cells [17]. CD24 has been reported to
be involved in the control of cell proliferation, apopto-
sis, and cell adhesion. CD24 gene encodes a sialoglyco-
protein that is expressed mainly on mature granulocytes,
premature lymphocytes, and epithelial and neural cells. The
encoded CD24 protein is anchored to the cell surface by
a glycosylphosphatidylinositol and acts as a ligand for P-
selectin on activated endothelial cells and platelets [18]. In
lymphocytes, CD24 can modulate the capacities of early T
and B lymphoid progenitor cells to proliferate and survive.
Antibody-mediated cross-linking of CD24 induces apoptosis
in a process involving the B-cell receptor and mitogen-
activated protein kinases [19]. CD24 expression is only
limited to several cell types in physiological condition. How-
ever, a large variety of tumors express CD24. For example,
CD24 is broadly overexpressed on esophageal squamous
cell carcinoma, small cell lung cancer, hepatocellular car-
cinoma, cholangiocarcinoma, pancreatic adenocarcinoma,
urothelial carcinoma, prostate carcinomas, ovarian cancer,
breast cancer, B-cell lymphomas, erythroleukemia, gliomas,
andprimaryneuroendocrinecarcinomas[8–15,20].Inmost
cancer types, CD24 expression is signiﬁcantly associated
with a more aggressive course of the disease, indicating
CD24 may play a role in the progression of cancer. In the
pancreatic cancers, Ikenaga et al. demonstrated that higher
tumor stage, nodal metastasis, and higher-grade tumors
were more frequent in the CD24-positive group compared
with the CD24-negative group. CD24 expression was also
associated with shorter survival in univariate analysis [21].
In addition, Lee et al. reported that the non-small-cell
lung carcinoma patients with CD24-high tumors tended to
have a higher risk of disease progression and cancer-related
death. Multivariate analysis proved CD24-high expression asJournal of Biomedicine and Biotechnology 5
Table 3: The expression of CD24 protein and clinicopathological features of retinoblastoma tissues with low risk of extraocular relapse.
Case no. Age/sex Clinicopathological features CD24 positivity (%)
12 2 m o n / M O D : W D 0
2 3/M OS: WD 10
3 3 mon/F OS: PD, Pre Lam ON Inv 30
4 8/F OD: PD, Pre Lam ON Inv 60
5 1 mon/F OD: PD, Pre Lam ON Inv 60
6 5 / F O D :M D ,F o c a lC h ,P r eL a mO NI n v 9 0
7 4 / F O D :M D ,F o c a lC hI n v 5 0
8 2/F OD: WD, Pre Lam ON Inv 70
9 3 / F O D :W D ,F o c a lC h ,P r eL a mO NI n v 5 0
10 2/M OS: PD, Focal Ch Inv 80
11 3/M OD: WD, Focal Ch Inv 60
12 3/M OS: PD 0
13 5/M OS: PD 0
14 1/F OD: WD 50
15 3/F OS: PD 0
16 4 mon/M OS: PD 0
17 2 mon/M OS: WD 0
18 2/M OD: PD 40
19 2/M OD: MD 10
20 16 mon/M OS: PD, Pre Lam ON Inv 70
21 6 mon/M OS: PD 30
22 2/M OD: WD 60
23 20 mon/M OD: WD 0
24 23 mon/M OS: PD 50
25 3 mon/M OD: PD 0
26 1/M OS: WD 0
27 5 mon/M OD: WD 30
28 1 mon/M OS: WD 20
29 3/M OS: PD 0
30 11 mon/M OD: MD 10
31 5/M OS: MD 0
32 2/F OS: PD 20
33 1/M OS: MD 0
34 4 mon/M OD: MD 0
35 5/M OS: PD, Pre Lam ON Inv 60
N o t e :m o n :m o n t h s ;M :m a l e ;F :f e m a l e ;O D :r i g h te y e ;O S :l e f te y e ;P D :p o o r l yd i ﬀerentiated; MD: moderately diﬀerentiated; WD: well diﬀerentiated; UL:
unilateral disease; BL: bilateral disease; Focal Ch Inv: focal invasion of tumor cells into choroids; Pre Lam ON Inv: pre-laminar invasion of optic nerve.
independent prognostic factors of disease progression and
cancer-related death [22]. Moreover, Sano group indicated
that CD24 expression was associated with lymph node
metastasis status, pathologic stage, number of nodal metas-
tases, lymphatic invasion status, and venous invasion status
of patients with esophageal squamous cell carcinoma. They
also concluded that the overexpression of CD24 was a novel
independent prognostic marker for identifying patients
with poor prognosis after curative resection of esophageal
squamous cell carcinoma [23]. In agreement with these
previous reports, our study demonstrated an overexpression
of CD24 in human retinoblastoma tissues, which also corre-
lated signiﬁcantly to the disease progression. Non-neoplastic
retina failed to show any detectable immunoreactivity for
CD24.
The signiﬁcance and clinical implications of CD24
expression in retinoblastoma tissues are yet to be elucidated.
In this study, the expression levels of CD24 protein in
patients with high risk of extraocular relapse were signiﬁ-
cantly higher than in patients with lower risk of extraocular
relapse. These results suggest tumor tissue CD24 may act as
a biomarker for prediction of the severity of retinoblastoma
and the prognosis of the patients.
In conclusion, this preliminary study has demonstrated
for the ﬁrst time that more than half of retinoblastoma
express the CD24 protein. Tissue levels of CD24 protein are6 Journal of Biomedicine and Biotechnology
increased in high-risk tumors compared to low-risk tumors.
Further functional studies are required to explore the role of
CD24 in retinoblastoma.
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